

## Supplementary Information

### An entropy-like index of bifurcational robustness for metabolic systems


Jimmy G. Lafontaine Rivera, Yun Lee & James C. Liao

#### Table of Contents

Simulation of natural perturbation .....	2
Optimized parameter values are biologically meaningful .....	3
References .....	4
Supplementary Table 1. Abbreviations used in Figure 1C and Figure 4B .....	5
Supplementary Table 2. Abbreviations used in Figure 4B .....	5

## Simulation of natural perturbation

To characterize the robustness of each model *in silico*, we performed 10,000 Monte Carlo simulations where the expression level of each enzyme, which is reflected in  $V_{max}$ , was subject to a random change. Starting from the default steady state, each perturbed model was simulated for sufficiently long to determine if a steady state (which need not be the default steady state) was reached (Supplementary Figure 1A). For a given model, we calculated the *in silico* probability of steady-state retention as the fraction of 10,000 simulations that reached a steady state. For simplicity, we investigated only perturbations in  $V_{max}$  and did not involve other kinetic parameters such as  $K_M$ , which could be similarly investigated.



**Supplementary Figure 1. Existing models have robustness problems to different extent.** The empirical probability of robustness, calculated as the fraction of 10,000 randomly perturbed models that retain a steady state, is shown for each of the 13 BioModels database models<sup>1-13</sup>. SD, the standard deviation of log fold change. CarbMetab, carbohydrate metabolism; RBCMetab, red blood cell metabolism; AspMetab, aspartate metabolism; FolateCyc, folate cycle; CalvinCyc, calvin cycle.

Each  $V_{\max}$  was subjected to F-fold changes, where  $F = V_{\max, \text{new}}/V_{\max, \text{default}}$ , and  $\log(F)$  was sampled from a normal distribution with mean = 0 and standard deviation = 0.5 (Fig. 1B). Apparently, models' robustness varied widely. Some models, such as the folate cycle model<sup>10</sup>, are very robust and almost always retain a steady state after perturbation. Others, such as Glycolysis-1<sup>12</sup>, Glycolysis-3<sup>11</sup>, and Glycolysis-4<sup>4</sup> responded poorly even to moderate perturbations, as only <60% of the models reach any steady state after perturbation. Interestingly, the difference in robustness can be dramatic even between models of the same metabolic pathway (*cf.* Glycolysis-1<sup>12</sup> and Glycolysis-2<sup>6</sup> yeast glycolysis models). This result suggests that not all descriptions of a native metabolic system perform equally well when subjected to perturbation. If one accepts the notion that these native pathways are robust against perturbations, the models did not describe such behavior.

One limitation of the Monte Carlo simulation is its scalability. The numerical integration of ODEs, while accurate, is computationally expensive and not scalable. Such scalability issues are most critical if the robustness calculation is to be coupled to highly iterative algorithms such as the ones used for model building and parameter fitting. For example, if we wish to re-fit the parameters of the non-robust models (*e.g.* Teusink *et al.*'s glycolysis model) so that the revised models could have higher bifurcational robustness, it is imperative that the quantification of robustness is accomplished in a more efficient and scalable way.

### **Optimized parameter values are biologically meaningful**

Figure 4B shows a comparison between the parameter set returned by an optimization considering robustness and the original parameter set used by Teusink *et al.*<sup>12</sup>. In the optimal set only four parameters ( $K_{\text{glyco}}$ ,  $K_{\text{treha}}$ ,  $V_{\text{pdc}}^m$ , and  $K_{\text{ATP}}$ ) required significant modifications; most parameters had little to no effect on the robustness and thus remained unchanged. Interestingly, the significant parameter modifications correspond with the adjustments made by van Heerden *et al.*<sup>14</sup> in their updated version of Teusink *et al.*'s model<sup>12</sup>. For example, both teams identified the need for adjustment in glycogen and trehalose production, the increase in pyruvate decarboxylase activity, and the consideration of phosphate dynamics as important features for

robustness. Overall, we demonstrate that a parameter optimization considering  $S$  can significantly improve the robustness of a metabolic model without any alteration to the kinetic rate expressions.

## References

- 1 Achcar, F., Kerkhoven, E. J., Bakker, B. M., Barrett, M. P. & Breitling, R. Dynamic modelling under uncertainty: the case of *Trypanosoma brucei* energy metabolism. *PLoS computational biology* **8**, e1002352, doi:10.1371/journal.pcbi.1002352 (2012).
- 2 Albert, M. A. *et al.* Experimental and *in silico* analyses of glycolytic flux control in bloodstream form *Trypanosoma brucei*. *The Journal of biological chemistry* **280**, 28306-28315, doi:10.1074/jbc.M502403200 (2005).
- 3 Chassagnole, C., Noisommit-Rizzi, N., Schmid, J. W., Mauch, K. & Reuss, M. Dynamic modeling of the central carbon metabolism of *Escherichia coli*. *Biotechnology and bioengineering* **79**, 53-73 (2002).
- 4 Conant, G. C. & Wolfe, K. H. Increased glycolytic flux as an outcome of whole-genome duplication in yeast. *Molecular systems biology* **3**, 129, doi:10.1038/msb4100170 (2007).
- 5 Curien, G. *et al.* Understanding the regulation of aspartate metabolism using a model based on measured kinetic parameters. *Molecular systems biology* **5**, 271, doi:10.1038/msb.2009.29 (2009).
- 6 Helfert, S., Estevez, A. M., Bakker, B., Michels, P. & Clayton, C. Roles of triosephosphate isomerase and aerobic metabolism in *Trypanosoma brucei*. *The Biochemical journal* **357**, 117-125 (2001).
- 7 Holzhutter, H. G. The principle of flux minimization and its application to estimate stationary fluxes in metabolic networks. *European journal of biochemistry / FEBS* **271**, 2905-2922, doi:10.1111/j.1432-1033.2004.04213.x (2004).
- 8 Laisk, A., Eichelmann, H. & Oja, V. C3 photosynthesis *in silico*. *Photosynth Res* **90**, 45-66 (2006).
- 9 Mosca, E. *et al.* Computational modeling of the metabolic States regulated by the kinase akt. *Frontiers in physiology* **3**, 418, doi:10.3389/fphys.2012.00418 (2012).
- 10 Nijhout, H. F., Reed, M. C., Budu, P. & Ulrich, C. M. A mathematical model of the folate cycle: new insights into folate homeostasis. *The Journal of biological chemistry* **279**, 55008-55016, doi:10.1074/jbc.M410818200 (2004).
- 11 Pritchard, L. & Kell, D. B. Schemes of flux control in a model of *Saccharomyces cerevisiae* glycolysis. *European journal of biochemistry / FEBS* **269**, 3894-3904 (2002).
- 12 Teusink, B. *et al.* Can yeast glycolysis be understood in terms of in vitro kinetics of the constituent enzymes? Testing biochemistry. *European journal of biochemistry / FEBS* **267**, 5313-5329 (2000).
- 13 Zhu, X.-G., de Sturler, E. & Long, S. P. Optimizing the distribution of resources between enzymes of carbon metabolism can dramatically increase photosynthetic rate: a numerical simulation using an evolutionary algorithm. *Plant Physiol* **145**, 513-526 (2007).
- 14 van Heerden, J. H. *et al.* Lost in Transition: Start-Up of Glycolysis Yields Subpopulations of Nongrowing Cells. *Science (New York, N.Y.)* **343**, 1245-1249 (2014).

**Supplementary Table 1. Abbreviations used in Figure 1C and Figure 4B**

<i>Abbreviation</i>	<i>Enzyme Name/Function</i>
<i>Glk</i>	Gluco kinase
<i>Pgi</i>	Phosphogluco isomerase
<i>Glyc</i>	Glycogen production
<i>Treha</i>	Trehalose production
<i>Pfk</i>	Phosphofruktokinase
<i>Aldo</i>	Fructose-1,6-bisphosphate aldolase
<i>Gapdh</i>	D-glyceraldehyde-3-phosphate dehydrogenase
<i>Pgk</i>	Phosphoglycerate kinase
<i>Pgm</i>	Phophoglycerate mutase
<i>Eno</i>	Phosphopyruvate hydratase
<i>Pyk</i>	Pyruvate kinase
<i>Pdc</i>	Pyruvate decarboxylase
<i>Succ</i>	Succinate production
<i>Glt</i>	Glucose transport
<i>Adh</i>	Alcohol dehydrogenase
<i>G3pdh</i>	Glycerol 3-phosphate dehydrogenase
<i>ATPase</i>	Adenosine triphosphatase

**Supplementary Table 2. Abbreviations used in Figure 4B**

<i>Abbreviation</i>	<i>Metabolite Name</i>
<i>NADH</i>	Reduced nicotinamide adenine dinucleotide
<i>P</i>	High energy phosphate pool ( $2[ATP] + [ADP]$ )
<i>ACE</i>	Acetaldehyde
<i>PYR</i>	Pyruvate
<i>PEP</i>	Phosphoenolpyruvate
<i>P2G</i>	2-phospho-D-glycerate
<i>P3G</i>	3-phospho-D-glycerate
<i>BPG</i>	1,3-biphospho-D-glycerate
<i>TRIO</i>	Dihydroxyacetone phosphate + glyceraldehyde-3-phosphate
<i>F16P</i>	Fructose-1-6-biphosphate
<i>F6P</i>	Fructose-6-phosphate
<i>G6P</i>	Glucose-6-phosphate
<i>GLCi</i>	Internal glucose